Kari Schmidt

THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

Angela C. Doran, R. Scott Obach, Bill J. Smith et al. · Drug Metabolism and Disposition · 2004 · 440 citations

The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice

Lin Zhou, Kari Schmidt, Frederick Nelson et al. · Drug Metabolism and Disposition · 2009 · 142 citations

P-Glycoprotein Contributes to the Blood-Brain, but Not Blood-Cerebrospinal Fluid, Barrier in a Spontaneous Canine P-Glycoprotein Knockout Model

Katrina L. Mealey, Stephen J. Greene, Rodney S. Bagley et al. · Drug Metabolism and Disposition · 2008 · 46 citations

Peripheral elevation of IGF-1 fails to alter Aβ clearance in multiple in vivo models

Thomas A. Lanz, Christopher T. Salatto, Anthony R. Semproni et al. · Biochemical Pharmacology · 2007 · 36 citations

Signal Transduction, Developmental Biology, Aβ Clearance +8

Oral bioavailability of P‐glycoprotein substrate drugs do not differ between<i>ABCB</i>1‐1Δ and<i>ABCB</i>1 wild type dogs

Katrina L. Mealey, Denise K. Waiting, David Raunig et al. · Journal of Veterinary Pharmacology and Therapeutics · 2010 · 31 citations